Answers are grounded in this paper and cite their sources.
Sulfonylureas remain widely prescribed for type 2 diabetes mellitus (T2DM), yet their use is strongly associated with hypoglycemia leading to emergency department visits, hospitalization, impaired awareness of hypoglycemia (IAH), and mortality. Available primary studies encompass heterogeneous study designs and populations ranging from dedicated sulfonylurea cohorts to mixed antidiabetic regimens. To identify and synthesize factors associated with hypoglycemia in T2DM patients treated with sulfonylureas. This literature review followed the PRISMA 2020 reporting flow via a structured PubMed search for English-language articles published between January 2016 and October 2026 (search conducted on October 15, 2026). Out of 121 identified records, two reviewers independently performed dual title/abstract screening and assessed 46 full-text articles for eligibility, yielding 17 included studies (13 Direct SU Evidence studies and 4 Mixed-Treatment Evidence studies). Methodological quality was appraised using Joanna Briggs Institute (JBI) Critical Appraisal Checklists, and data were synthesized narratively without meta-analysis due to heterogeneity across study designs and hypoglycemia outcome definitions. JBI appraisal rated 16 studies as high quality and 1 pilot study as moderate quality. Factors consistently associated with increased hypoglycemia included: (1) patient factors: older age (≥ 65 to ≥ 75 years; aIRR = 2.41; 95% CI 1.69–3.44), Black Caribbean (aIRR = 1.63), Black African (aIRR = 1.90), and Indian (aIRR = 1.93) ethnicity, cognitive impairment, and lack of structured diabetes education; (2) clinical factors: prior hypoglycemia hospitalization (aOR = 16.44; 95% CI 1.74–154.33), tight glycemic control with HbA1c < 7.0% in SU cohorts (aHR = 1.54; 95% CI 1.27–1.87) and adults aged ≥ 70 years on SU/insulin (aHR = 2.52; 95% CI 2.23–2.84), and impaired renal function (eGFR < 30 mL/min/1.73 m²); (3) treatment factors: second-line addition/switching to SUs (aHR = 7.60; 95% CI 4.64–12.44), metformin + SU versus DPP-4 inhibitors (aHR = 2.07; 95% CI 1.61–2.66), long-acting pancreas-nonspecific SUs (glyburide/glimepiride) versus short-acting pancreas-specific SUs (gliclazide/glipizide/tolbutamide) (aHR = 2.83; 95% CI 1.64–4.88), and SU duration ≥ 5 years for IAH (aOR = 3.06–3.56); and (4) concomitant drug interactions with amiodarone (weighted HR = 1.92; 95% CI 1.12–3.30) or warfarin (aHR = 1.38; 95% CI 1.10–1.75). Conversely, metabolic markers (low basal β-cell function HOMA-2%β [aIRR = 1.74] and elevated fasting insulin [ρ = 0.390]) showed exploratory associations, whereas CYP2C9 (2/3; aOR = 0.80; p = 0.30), KCNJ11, and ABCC8 variants showed no significant association. Hypoglycemia in T2DM patients using sulfonylureas is associated with a multidomain interplay of patient, clinical, treatment, and drug-interaction factors, with varying strength of evidence across study designs.
No takes yet. Share an insight, caveat, or question.
Enjiska et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: